Evidence map›Paper›PMID 37438770›Full record

ArticleAlzheimer's research & therapy2023

Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults.

Emma S Luckett, Magdalena Zielonka, Amine Kordjani, Jolien Schaeverbeke, Katarzyna Adamczuk, Steffi De Meyer, Koen Van Laere, Patrick Dupont, Isabelle Cleynen, Rik Vandenberghe

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. [Targets and Molecular Mechanisms of Salidroside in Improving High-Altitude Cognitive Function].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Effect of choline supplementation in presymptomaticAlzheimer's & dementia (New York, N. Y.)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Emma S LuckettLaboratory for Cognitive Neurology, Leuven Brain Institute, KU Leuven, Leuven, 3000, Belgium.
Magdalena ZielonkaAlzheimer Research Centre KU Leuven, Leuven Brain Institute, Leuven, 3000, Belgium.
Amine KordjaniLaboratory for Complex Genetics, KU Leuven, Leuven, 3000, Belgium.
Jolien SchaeverbekeLaboratory for Cognitive Neurology, Leuven Brain Institute, KU Leuven, Leuven, 3000, Belgium.
Katarzyna AdamczukBioClinica, Newark, CA, USA.
Steffi De MeyerLaboratory for Cognitive Neurology, Leuven Brain Institute, KU Leuven, Leuven, 3000, Belgium.
Koen Van LaereDivision of Nuclear Medicine, UZ Leuven, Leuven, 3000, Belgium.
Patrick DupontLaboratory for Cognitive Neurology, Leuven Brain Institute, KU Leuven, Leuven, 3000, Belgium.
Isabelle Cleynen *Laboratory for Complex Genetics, KU Leuven, Leuven, 3000, Belgium.
Rik Vandenberghe *Laboratory for Cognitive Neurology, Leuven Brain Institute, KU Leuven, Leuven, 3000, Belgium. rik.vandenberghe@uz.kuleuven.ac.be.
KU Leuven · BEVIB-KU Leuven Center for Brain & Disease Research · BEBioClinica (United States) · USVIB-KU Leuven Center for Microbiology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGene expression is dysregulated in Alzheimer's disease (AD) patients, both in peripheral blood and post mortem brain. We investigated peripheral whole-blood gene (co)expression to determine molecular changes prior to symptom onset.

methodsRNA was extracted and sequenced for 65 cognitively healthy F-PACK participants (65 (56-80) years, 34 APOE4 non-carriers, 31 APOE4 carriers), at baseline and follow-up (interval: 5.0 (3.4-8.6) years). Participants received amyloid PET at both time points and amyloid rate of change derived. Accumulators were defined with rate of change ≥ 2.19 Centiloids. We performed differential gene expression and weighted gene co-expression network analysis to identify differentially expressed genes and networks of co-expressed genes, respectively, with respect to traits of interest (APOE4 status, amyloid accumulation (binary/continuous)), and amyloid positivity status, followed by Gene Ontology annotation.

resultsThere were 166 significant differentially expressed genes at follow-up compared to baseline in APOE4 carriers only, whereas 12 significant differentially expressed genes were found only in APOE4 non-carriers, over time. Among the significant genes in APOE4 carriers, several had strong evidence for a pathogenic role in AD based on direct association scores generated from the DISQOVER platform: NGRN, IGF2, GMPR, CLDN5, SMIM24. Top enrichment terms showed upregulated mitochondrial and metabolic pathways, and an exacerbated upregulation of ribosomal pathways in APOE4 carriers compared to non-carriers. Similarly, there were 33 unique significant differentially expressed genes at follow-up compared to baseline in individuals classified as amyloid negative at baseline and positive at follow-up or amyloid positive at both time points and 32 unique significant differentially expressed genes over time in individuals amyloid negative at both time points. Among the significant genes in the first group, the top five with the highest direct association scores were as follows: RPL17-C18orf32, HSP90AA1, MBP, SIRPB1, and GRINA. Top enrichment terms included upregulated metabolism and focal adhesion pathways. Baseline and follow-up gene co-expression networks were separately built. Seventeen baseline co-expression modules were derived, with one significantly negatively associated with amyloid accumulator status (r

conclusionsWe show that there are longitudinal gene expression changes that implicate a disrupted immune system, protein removal, and metabolism in cognitively intact individuals who carry APOE4 or who accumulate in cortical amyloid. This provides insight into the pathophysiology of AD, whilst providing novel targets for drug and therapeutic development.

Indexed as

Alzheimer DiseaseApolipoprotein E4AgedAged, 80 and overAmyloidogenic ProteinsGene Expression ProfilingHumansMiddle AgedTranscription FactorsTranscriptomeAmyloidogenic ProteinsApolipoprotein E4Transcription FactorsAlzheimer’s diseaseAmyloid accumulationAPOE4BloodLongitudinal studyRNA sequencingTranscriptome

Identifiers

PMID37438770
PMCPMC10337180
OpenAlexW4384030795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.